Summary
This past spring, the Center for Medicare and Medicaid Innovation (CMMI or Innovation Center) announced significant changes to its model portfolio, including the early termination of several models at the end of 2025, actions projected to save $750 million. The Innovation Center also abandoned the Medicare $2 Drug List and Accelerating Clinical Evidence models and signaled it would potentially scale-back the Integrated Care for Kids Model. Several months later, CMMI released a new strategic framework emphasizing prevention, individual engagement, and market-based mechanisms, and subsequently announced nine new models as well as modifications to several existing models.
Ultimately, CMMI oversaw the closeout of seven models and the launch of six new models in 2025. Looking ahead, the Innovation Center plans to initiate at least nine new models and sunset two existing models in 2026, putting the agency’s portfolio at 19 active models by year’s end, assuming no further changes.
Click here for an alphabetical catalogue of the 16 currently active and 5 announced Innovation Center models as of January 9, 2025. Expanded models (i.e., the Home Health Value Based Purchasing Model and the Medicare Diabetes Prevention Program) and models that have been indefinitely delayed (e.g., Radiation Oncology Model) are not included.